In December 2019, viral pneumonia (Covid-19) caused by a novel beta-coronavirus (SARS-CoV-2) broke out in Wuhan, China. Some patients rapidly progressed and suffered severe acute respiratory failure and died, making it imperative to develop a safe and effective vaccine to treat and prevent severe Covid-19 pneumonia. Based on detailed analysis of the viral genome and search for potential immunogenic targets, a synthetic minigene has been engineered based on conserved domains of the viral structural proteins and a polyprotein protease. The infection of Covid-19 is mediated through binding of the Spike protein to the ACEII receptor, and the viral replication depends on molecular mechanisms of all of these viral proteins. This trial proposes to develop universal vaccine and test innovative Covid-19 minigenes engineered based on multiple viral genes, using an efficient lentiviral vector system (NHP/TYF) to express viral proteins and immune modulatory genes to modify artificial antigen presenting cells (aAPC) and to activate T cells. In this study, the safety and immune reactivity of this aAPC vaccine will be investigated.
Background:
The 2019 discovered new coronavirus, SARS-CoV-2, is an enveloped positive strand single
strand RNA virus. The number of SARS-CoV-2 infected people has increased rapidly and WHO has
warned that the pandemic spread of Covid-19 is imminent and would have disastrous outcomes.
Covid-19 could pose a serious threat to human health and the global economy. There is no
vaccine available or clinically approved antiviral therapy as yet. This study aims to
evaluate the safety and immune reactivity of a genetically modified aAPC universal vaccine to
treat and prevent Covid-19.
Objective:
Primary study objectives: Injection of Covid-19/aAPC vaccine to volunteers to evaluate the
safety.
Secondary study objectives: To evaluate the anti- Covid-19 reactivity of the Covid-19/aAPC
vaccine.
Design:
1. Based on the genomic sequence of the new coronavirus SARS-CoV-2, select conserved and
critical structural and protease protein domains to engineer lentiviral minigenes to
express SARS-CoV-2 antigens.
2. The Covid-19/aAPC vaccine is prepared by applying lentivirus modification including
immune modulatory genes and the viral minigenes, to the artificial antigen presenting
cells (aAPCs). The Covid-19/aAPCs are then inactivated for proliferation and extensively
safety tested.
3. The subjects receive a total of 5x10^ 6 cells each time by subcutaneous injection at 0,
14 and 28 days. The subjects are followed-up with peripheral blood tests at 0, 14, 21,
28 and 60 days until the end of the test.
Biological: Pathogen-specific aAPC
The subjects will receive three injections of 5x10^6 each Covid-19/aAPC vaccine via subcutaneous injections.
Inclusion Criteria:
- Healthy and Covid-19-positive volunteers
- The interval between the onset of symptoms and randomized is within 7 days in Covid-19
patients. The onset of symptoms is mainly based on fever. If there is no fever, cough
or other related symptoms can be used;
- White blood cells ≥ 3,500/μl, lymphocytes ≥ 750/μl;
- Human immunodeficiency virus (HIV), hepatitis B virus (HBV), hepatitis C virus (HCV)
or tuberculosis (TB) test negative;
- Sign the Informed Consent voluntarily;
Exclusion Criteria:
- Subject with active HCV, HBV or HIV infection.
- Subject is albumin-intolerant.
- Subject with life expectancy less than 4 weeks.
- Subject participated in other investigational vaccine therapies within the past 60
days.
- Subject with positive pregnancy test result.
- Researchers consider unsuitable.
Shenzhen Geno-immune Medical Institute
Shenzhen, Guangdong, China
Investigator: Lung-Ji Chang
Contact: 86-755-86725195
c@szgimi.org
Lung-Ji Chang
+86(755)8672 5195
c@szgimi.org
Lung-Ji Chang, Principal Investigator
Shenzhen Geno-Immune Medical Institute